Covance, Inc. has acquired the assets of Signet Laboratories, Inc. for $9 million. Signet is based in Dedham, MA and is a provider of monoclonal antibodies used in the research of cancer, infectious disease and neurodegenerative disease. “This acquisition strengthens Covance’s leadership position in providing antibodies and detection reagents that support early drug development discovery work,” said Joe Herring, Covance’s chairman and chief executive officer. “...